Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15657067
Thelemann A, et al. (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4, 356-76 15657067
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
erlotinib decrease

Y727-p - EGFR (human)
Modsite: sGAFGtVykGLWIPE SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y727‑p, EGFR iso2 (human): , EGFR iso5 (human): Y727‑p, EGFR (mouse): Y729‑p, EGFR (rat): Y728‑p, EGFR (pig): Y727‑p

Y764-p - EGFR (human)
Modsite: kEILDEAyVMAsVDN SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y764‑p, EGFR iso2 (human): , EGFR iso5 (human): Y764‑p, EGFR (mouse): Y766‑p, EGFR (rat): Y765‑p, EGFR (pig): Y764‑p

Y869-p - EGFR (human)
Modsite: LGAEEkEyHAEGGkV SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y869‑p, EGFR iso2 (human): , EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y944-p - EGFR (human)
Modsite: PICtIDVyMIMVKCW SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y944‑p, EGFR iso2 (human): , EGFR iso5 (human): Y944‑p, EGFR (mouse): Y946‑p, EGFR (rat): Y945‑p, EGFR (pig): Y944‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y978-p - EGFR (human)
Modsite: MARDPQRyLVIQGDE SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y978‑p, EGFR iso2 (human): , EGFR iso5 (human): Y978‑p, EGFR (mouse): Y980‑p, EGFR (rat): Y979‑p, EGFR (pig): Y978‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

S991-p - EGFR (human)
Modsite: DERMHLPsPtDsNFy SwissProt Entrez-Gene
Orthologous residues
EGFR (human): S991‑p, EGFR iso2 (human): , EGFR iso5 (human): S991‑p, EGFR (mouse): S993‑p, EGFR (rat): S992‑p, EGFR (pig): S991‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y998-p - EGFR (human)
Modsite: sPtDsNFyRALMDEE SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y998‑p, EGFR iso2 (human): , EGFR iso5 (human): Y998‑p, EGFR (mouse): Y1000‑p, EGFR (rat): Y999‑p, EGFR (pig): Y998‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y1016-p - EGFR (human)
Modsite: DVVDADEyLIPQQGF SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1016‑p, EGFR iso2 (human): , EGFR iso5 (human): Y1016‑p, EGFR (mouse): Y1018‑p, EGFR (rat): Y1017‑p, EGFR (pig): Y1016‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1069-p - EGFR (human)
Modsite: EDsFLQRyssDPtGA SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1069‑p, EGFR iso2 (human): , EGFR iso5 (human): Y1069‑p, EGFR (mouse): Y1069‑p, EGFR (rat): Y1068‑p, EGFR (pig): Y1068‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1092-p - EGFR (human)
Modsite: tFLPVPEyINQsVPk SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1092‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1110-p - EGFR (human)
Modsite: GsVQNPVyHNQPLNP SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1110‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1138-p - EGFR (human)
Modsite: tAVGNPEyLNtVQPt SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1138‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1138‑p, EGFR (rat): Y1137‑p, EGFR (pig): Y1137‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y1172-p - EGFR (human)
Modsite: IsLDNPDyQQDFFPk SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1172‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1172‑p, EGFR (rat): Y1171‑p, EGFR (pig): Y1171‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1197-p - EGFR (human)
Modsite: stAENAEyLRVAPQS SwissProt Entrez-Gene
Orthologous residues
EGFR (human): Y1197‑p, EGFR iso2 (human): , EGFR iso5 (human): , EGFR (mouse): Y1197‑p, EGFR (rat): Y1196‑p, EGFR (pig): Y1196‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
erlotinib decrease

Y1112-p - HER2 (human)
Modsite: DPsPLQRySEDPTVP SwissProt Entrez-Gene
Orthologous residues
HER2 (human): Y1112‑p, HER2 iso2 (human): Y502‑p, HER2 iso5 (human): Y1082‑p, HER2 (mouse): Y1113‑p, HER2 (rat): Y1114‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y249-p - P130Cas (human)
Modsite: APGPQDIyDVPPVRG SwissProt Entrez-Gene
Orthologous residues
P130Cas (human): Y249‑p, P130Cas iso2 (human): Y267‑p, P130Cas iso7 (human): Y267‑p, P130Cas iso8 (human): Y249‑p, P130Cas (mouse): Y253‑p, P130Cas (rat): Y347‑p, P130Cas iso2 (rat): Y253‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y306-p - P130Cas (human)
Modsite: PsNHHAVyDVPPsVs SwissProt Entrez-Gene
Orthologous residues
P130Cas (human): Y306‑p, P130Cas iso2 (human): Y324‑p, P130Cas iso7 (human): Y324‑p, P130Cas iso8 (human): Y306‑p, P130Cas (mouse): Y310‑p, P130Cas (rat): Y404‑p, P130Cas iso2 (rat): Y310‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y387-p - P130Cas (human)
Modsite: RPGPGtLyDVPRERV SwissProt Entrez-Gene
Orthologous residues
P130Cas (human): Y387‑p, P130Cas iso2 (human): Y405‑p, P130Cas iso7 (human): Y405‑p, P130Cas iso8 (human): Y387‑p, P130Cas (mouse): Y391‑p, P130Cas (rat): Y485‑p, P130Cas iso2 (rat): Y391‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
erlotinib IGF-1 inhibit treatment-induced increase

Y88-p - PXN iso2 (human)
Modsite: PQsssPVyGssAKTs SwissProt Entrez-Gene
Orthologous residues
PXN (human): Y88‑p, PXN iso2 (human): Y88‑p, PXN iso3 (human): Y88‑p, PXN iso6 (human): Y95‑p, PXN (mouse): Y88‑p, PXN iso2 (mouse): Y88‑p, PXN (rat): Y88‑p, PXN (chicken): Y88‑p, PXN (cow): Y82‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human

Y118-p - PXN iso2 (human)
Modsite: VGEEEHVysFPNKQK SwissProt Entrez-Gene
Orthologous residues
PXN (human): Y118‑p, PXN iso2 (human): Y118‑p, PXN iso3 (human): Y118‑p, PXN iso6 (human): Y125‑p, PXN (mouse): Y118‑p, PXN iso2 (mouse): Y118‑p, PXN (rat): Y118‑p, PXN (chicken): Y118‑p, PXN (cow): Y112‑p
Characterization
Methods used to characterize site in vivo mass spectrometry, phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
LPA increase

Y239-p - SHC1 iso2 (human)
Modsite: EEPPDHQyyNDFPGK SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y349‑p, SHC1 iso2 (human): Y239‑p, SHC1 iso3 (human): Y194‑p, SHC1 iso6 (human): Y349‑p, SHC1 iso7 (human): Y239‑p, SHC1 (mouse): Y349‑p, SHC1 iso2 (mouse): Y239‑p, SHC1 iso3 (mouse): Y194‑p, SHC1 (rat): Y349‑p, SHC1 iso2 (rat): Y239‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 no change compared to control
LPA no change compared to control

Y240-p - SHC1 iso2 (human)
Modsite: EPPDHQyyNDFPGKE SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y350‑p, SHC1 iso2 (human): Y240‑p, SHC1 iso3 (human): Y195‑p, SHC1 iso6 (human): Y350‑p, SHC1 iso7 (human): Y240‑p, SHC1 (mouse): Y350‑p, SHC1 iso2 (mouse): Y240‑p, SHC1 iso3 (mouse): Y195‑p, SHC1 (rat): Y350‑p, SHC1 iso2 (rat): Y240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  HN5 (squamous)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 no change compared to control
LPA no change compared to control